Statin induced diabetes and its clinical implications

Journal of Pharmacology and Pharmacotherapeutics

Volumn 5, Issue 3, 2014, Pages 181-185

  Aiman, Umme ^a   Najmi, Ahmad ^b   Khan, Rahat Ali ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b Index Medical College   (India)

Author keywords

Cardiovascular disease; insulin resistance; statins; type 2 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADIPONECTIN; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; UBIDECARENONE; VITAMIN D;

DIABETES MELLITUS; DIABETOGENESIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DOSE REGIMEN; DRUG USE; EVIDENCE BASED MEDICINE; GENDER BIAS; GLUCOSE HOMEOSTASIS; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); PATIENT MONITORING; PERSONALIZED MEDICINE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCREENING TEST; TREATMENT INDICATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84905701191     PISSN: 0976500X     EISSN: 09765018     Source Type: Journal    
DOI: 10.4103/0976-500X.136097     Document Type: Review

References (32)

1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
2. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.
3. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-30.
4. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: Results from the LIPID trial. Diabetes Care 2003;26:2713-21.
5. Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: A meta-analysis of randomized controlled trials. Curr Med Res Opin 2008;24:1359-62.
6. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: A meta-analysis. Diabetes Care 2009;32:1924-9.
7. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
8. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 2011;305:2556-64.
9. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 2012;380:565-71.
10. Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013;111:1123-30.
11. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+signalling and insulin secretion due to blockade of L-type Ca2+channels in rat islet beta-cells. Br J Pharmacol 1999;126:1205-13.
12. Mabuchi H, Higashikata T, Kawashiri M, Katsuda S, Mizuno M, Nohara A, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 2005;12:111-9.
13. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001;507:357-61.
14. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): Implications in glycaemic control. Diabetologia 2006;49:1881-92.
15. Ganesan S, Ito MK. Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes. Metab Syndr Relat Disord 2013;11:251-5.
16. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Park JB, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009;204:483-90.
17. Koh KK, Quon MJ, Sakuma I, Han SH, Choi H, Lee K, et al. Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. Int J Cardiol 2013;166:509-15.
18. Supale S, Li N, Brun T, Maechler P. Mitochondrial dysfunction in pancreatic βcells. Trends Endocrinol Metab 2012;23:477-87.
19. Phielix E, Mensink M. Type 2 diabetes mellitus and skeletal muscle metabolic function. Physiol Behav 2008;94:252-8.
20. Wang CH, Wang CC, Huang HC, Wei YH. Mitochondrial dysfunction leads to impairment of insulin sensitivity and adiponectin secretion in adipocytes. FEBS J 2013;280:1039-50.
21. Sirvent P, Fabre O, Bordenave S, Hillaire-Buys D, Raynaud De Mauverger E, Lacampagne A, et al. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol 2012;259:263-8.
22. Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: Findings from the National Health and Nutrition Examination Survey III. PLoS One 2010;5:e10805.
23. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol 2005;19:117-25.
24. Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. Diabetes Res Clin Pract 2010;87:98-107.
25. Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: A sex-based meta-analysis. Arch Intern Med 2012;172:909-19.
26. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172:144-52.
27. Ferenczi EA, Asaria P, Hughes AD, Chaturvedi N, Francis DP. Can a statin neutralize the cardiovascular risk of unhealthy dietary choices? Am J Cardiol 2010;106:587-92.
28. Niederdeppe J, Byrne S, Avery RJ, Cantor J. Direct-to-consumer television advertising exposure, diagnosis with high cholesterol, and statin use. J Gen Intern Med 2013;28:886-93.
29. Johansen ME, Gold KJ, Sen A, Arato N, Green LA. A national survey of the treatment of hyperlipidemia in primary prevention. JAMA Intern Med 2013;173:586-8.
30. Alvarez JA, Ashraf A. Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol 2010;2010:351385.
31. Talaei A, Mohamadi M, Adgi Z. The effect of vitamin D on insulin resistance in patients with type 2 diabetes. Diabetol Metab Syndr 2013;5:8.
32. Yamazaki T, Kishimoto J, Ito C, Noda M, Odawara M, Terauchi Y, et al. Japan prevention trial of diabetes by pitavastatin in patients with impaired glucose tolerance (The J-PREDICT study): Rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int 2011;2:134-40.